Successful Response of Oral Etoposide for Refractory Neuroblastoma / 대한소아혈액종양학회지
Korean Journal of Pediatric Hematology-Oncology
; : 115-120, 2003.
Article
de Ko
| WPRIM
| ID: wpr-115283
Bibliothèque responsable:
WPRO
ABSTRACT
Intensive chemotherapy with or without stem cell rescue has become widely accepted for treatment of neuroblastoma because increased dose-intensity correlates with improved response rates. For neuroblastoma that is resistant to intensive chemotherapy, further use of high-dose therapy is unlikely to be beneficial. For disease that recurs after myeloablative consolidation, high-dose salvage therapy may not be feasible because of poor bone marrow reserve and may not be justified in view of its morbidity in the absence of a realistic chance for cure. One treatment option in these difficult clinical settings is chronic oral administration of low-dose etoposide. However, there has been a few clinical reports for the experience of oral etoposide for refractory neuroblastoma. We now present 2 cases of successful response of oral etoposide for refractory neuroblastoma.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Cellules souches
/
Moelle osseuse
/
Administration par voie orale
/
Thérapie de rattrapage
/
Traitement médicamenteux
/
Étoposide
/
Neuroblastome
langue:
Ko
Texte intégral:
Korean Journal of Pediatric Hematology-Oncology
Année:
2003
Type:
Article